Overview

NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

Status:
Terminated
Trial end date:
2020-10-09
Target enrollment:
Participant gender:
Summary
This is a first-in-human trial proposed to test HLA-A*0201 restricted NY-ESO-1 redirected T cells with edited endogenous T cell receptor and PD-1.
Phase:
Phase 1
Details
Lead Sponsor:
University of Pennsylvania
Collaborators:
Parker Institute for Cancer Immunotherapy
Tmunity Therapeutics
Treatments:
Cyclophosphamide
Fludarabine